ADC Therapeutics SA (ADCT)
NYSE: ADCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ADCT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $202.99M
- EPS (TTM)
- -$0.67
- Dividend yield
- None
- 52-week range
- 0.78 – 4.98
- Day range
- 1.32 – 1.63
- Volume / Avg
- 5.54M / 1.43M
- Beta
- —
- Shares outstanding
- 127.67M
52-week range
ADCT stock today
On Oct 8, ADCT ended the session at $1.59, adding $0.17 (11.97%), versus the S&P 500's 0.47% decline. Volume was 3.9x the average at 5.54M shares, a sign of unusually heavy trading. At this level, ADCT sits near the bottom of its 52-week range of $0.78 to $4.98: 68.1% below the high, set on Mar 11, 2026 and 103.8% above the low.
ADCT is down 55.0% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 65.0%. ADC Therapeutics SA has posted a net loss over the last twelve months (EPS of -$0.67), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About ADC Therapeutics SA
Company profileADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Ameet Mallik M.B.A., M.S.
- Headquarters
- Epalinges
- Employees
- 188
- IPO year
- 2020
- Website
- adctherapeutics.com
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$3.33+109.43%
- Strong buy 0
- Buy 3
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
ADC Therapeutics SA peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RNACCartesian Therapeutics Inc. | 6.82 | +2.10% | $206.34M | vs ADCT |
| ELDNEledon Pharmaceuticals Inc. | 2.42 | 0.00% | $196.65M | vs ADCT |
| TRDAEntrada Therapeutics Inc. | 5.53 | -1.43% | $215.32M | vs ADCT |
| LYELLyell Immunopharma Inc. | 8.79 | +2.69% | $215.40M | vs ADCT |
| NGENNervGen Pharma Corp. | 1.75 | +0.57% | $188.16M | vs ADCT |
| YARWYarrow Bioscience Inc. | 19.87 | +5.83% | $184.88M | vs ADCT |
| NATRNature's Sunshine Products Inc. | 12.57 | -0.16% | $221.18M | vs ADCT |
| SIONSionna Therapeutics Inc. | 4.90 | +1.66% | $221.24M | vs ADCT |
Indexes, lists and sector
ADC Therapeutics SA stock FAQ
What is ADC Therapeutics SA's stock price today?
ADCT last traded at $1.59 as of Oct 8, 4:00 PM EDT, up 11.97% on the day. Prices are delayed at least 15 minutes.
Who is ADC Therapeutics SA's CEO?
Dr. Ameet Mallik M.B.A., M.S. is the chief executive officer of ADC Therapeutics SA, which has about 188 employees.
What is the ADCT 52-week high?
The 52-week high for ADCT is $4.98 and the 52-week low is $0.78. The stock is currently 68.1% below its high.